224 results on '"Rubinstein E."'
Search Results
2. Implications of Shale Gas Well Integrity Failure Near a Longwall Mine Under Shallow Cover
3. Evaluating the Short-Term Environmental and Clinical Effects of a Radiation Oncology Department's Response to the COVID-19 Pandemic (STEER COVID-19)
4. INNOVATIVE DEVELOPMENT OF THE RUSSIAN FEDERATION: ECONOMIC INSTRUMENTS OF STATE SUPPORT FOR THE IMPLEMENTATION OF INNOVATIONS
5. Practices and perspectives of primary care physicians in Japan and the United States about diagnosing dementia: a qualitative study
6. Assessing anti-estrogenic effects of AHR ligands in primary human and rat endometrial epithelial cells
7. PIN80 DOES TIME IMPACT HTA DECISIONS IN INFECTIOUS DISEASES?
8. PDG74 AVAILABILITY OF FDA-APPROVED SURROGATE MARKERS IN REAL-WORLD DATA
9. Future antibiotics and current practices for treating respiratory tract infections
10. The Relationship of Pulsatile Cerebrospinal Fluid Flow to Cerebral Blood Flow and Intracranial Pressure: A New Theoretical Model
11. Future Aspects
12. Acinetobacter Infections in Intensive Care Units
13. How IL-2 can affect melanoma cells
14. Dynamic regulation of CD45 by tetraspanin CD53
15. Primary endometrial 3D co-cultures: A comparison between human and rat endometrium
16. GH3 and RC-4BC cell lines are not suitable as in vitro models to study prolactin modulation and AHR responsiveness in rat pituitary
17. Detectability of a self-illuminating lifeline for self-escape in smoke conditions of an underground mine
18. Expression and Role of Surface Markers of Immunocompetent Cells in Non Lymphoid Systems
19. JUNO, the receptor of sperm IZUMO1, is expressed by the human oocyte and is essential for human fertilisation
20. PRM7 - THE USE OF NATURAL LANGUAGE PROCESSING TO ASSESS PATIENTS WITH BLEEDS IN THEIR NOTES IN THE OPTUM EHR DATABASE
21. PSY65 - REAL-WORLD DATA ANALYSIS OF US CLAIMS DATA ON COAGULATION FACTOR IX DISPENSATION AND EXPENDITURES IN PATIENTS WITH SEVERE HEMOPHILIA B: STANDARD HALF-LIFE VS. EXTENDED HALF-LIFE PRODUCTS
22. Real World Factor Dispensation and Expenditures in us Patients with Hemophilia B: Standard Half-Life vs. Extended Half-Life Factor IX Replacement Products
23. Factor Dispensation and Expenditures in Hemophilia B Patients Switching from Standard Half-Life to Extended Half-Life Recombinant Factor IX Replacement Products: Real-World Analysis in Japan
24. Real World Data Analysis of US Claims Database on Coagulation Factor IX Expenditures in Patients with Hemophilia B: Standard half-Life Vs. Extended Half-Life Products
25. Influence of vancomycin minimum inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus left-sided infective endocarditis treated with antistaphylococcal β-lactam antibiotics: a prospective cohort study by the International Collaboration on Endocarditis
26. Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis
27. Prone positioning decreases cardiac output and increases systemic vascular resistance in neonates
28. Potential Role for Telavancin in Bacteremic Infections Due to Gram-Positive Pathogens: Focus on Staphylococcus aureus
29. Penetration of Ciprofloxacin into Female Pelvic Tissues
30. Nice Restrictiveness Compared To the Market Authorization
31. Nice Restrictiveness Compared to the Market Authorization In Oncology And Non-Oncology Reviews
32. Comparison between transthoracic and transesophageal echocardiography in screening for infective endocarditis in patients with Staphylococcus aureus bacteremia
33. Does the use of a surrogate outcome in solid state oncology htas decrease the chances of positive recommendations?
34. A Regulatory Compararison Of Non-Insulin Dependent Type Ii Diabetes Drug Approvals In The United States And European Union
35. Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure
36. HIV Regulatory Practices and Their Influence Over Reimbursement Decisions
37. A Case Study of FDA Practices and Its Influence on Regulatory and Reimbursement Decisions for Darunavir
38. Patient-Reported Outcomes (Pros) In Diabetes Clinical Trials
39. O-22 Embryo biopsy for PGD has no significant impact on neonatal outcome
40. A comparison of outcomes in clinical trials conducted within the united states versus outside the united states
41. PRM152 Is it Just Semantics? The Use of “Efficacy” and “Effectiveness” in Comparative Effectiveness Reviews and Health Technology Assessments
42. PIH55 Use of PRO Analysis in Health Technology Assessments
43. The responses of Aboriginal Canadians to adjuvanted pandemic (H1N1) 2009 influenza vaccine
44. PCV28 CARDIOVASCULAR RISK FACTORS AMONG CHINESE AND WHITE ADULTS IN THE UNITED STATES
45. PCV28 CARDIOVASCULAR RISK FACTORS AMONG ASIAN INDIAN AND WHITE ADULTS IN THE UNITED STATES
46. Modelling the Transmission Dynamics and Control of the Novel 2009 Swine Influenza (H1N1) Pandemic
47. Systemic MRSA infections
48. Bacteremic nosocomial pneumonia cases from the ATTAIN studies
49. Late ventilator-associated pneumonia: analysis of baseline characteristics and clinical outcomes in the ATTAIN studies
50. Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given with Routine Pediatric Vaccinations in Canada
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.